Search Results - "Kasle, Adam"

Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America by Pescott, Chris, Kasle, Adam, Esteso, Federico, Stefani, Stephen, Brust, Leandro, Pinto, Jose, Tilli, Malena, Massello, Matthew

“…Abstract only 203 Background: Anti-EGFR treatment of RAS wild-type metastatic colorectal cancer (mCRC) in Latin America includes cetuximab or panitumumab,…”
Get full text

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA by Elsea, David, Muston, Dominic, Fan, Lin, Mihai, Adela, Meng, Yang, Kasle, Adam, Monberg, Matthew

“…Background Poly(ADP-ribose) polymerase inhibitor maintenance treatments are available for platinum-sensitive advanced ovarian cancer. Olaparib (O) is available…”
Get full text

Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States by Carlson, Josh, Foos, Volker, Kasle, Adam, Mugwagwa, Tendai, Draica, Florin, Lee Wiemken, Timothy, Nguyen, Jennifer L., Cha-Silva, Ashley, Migliaccio-Walle, Kristen, Dzingina, Mendy

“…Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of patients with mild-to-moderate COVID-19 at high…”
Get full text